GalNAc-L96, a triantennary GalNAc ligand that efficiently binds to ASGPR, enables the synthesis of GalNAc-siRNA for enhanced hepatocyte targeting. T1 acts as a key intermediate in the synthesis of GalNAc-L96, aiding in the creation of precision therapeutic agents.
Molecular Weight
174.24
Molecular Formula
C8H18N2O2
Form
Solid
Purity
≥98%, determined by HPLC.
Impurities
Free from inappropriate visible particulates, foreign matter, discoloration, or other defects.
Identity
Conforms to structure, determined by 1H NMR.
Test Method
NMR; HPLC
Publications
Publications (0)
×
Publications
Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.
As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.
*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.